Audit: QRS - Mucuna pruriens for Health & Longevity
Audit conducted on 20/08/2026 01:48 using AI4L / Opus 5
Summary
| Items | Count |
|---|---|
| Total | 93 |
| Passed | 83 |
| Failed | 0 |
| N/A | 10 |
| Pass Rate | 100.00% |
- Total = Passed + Failed + N/A
- Pass Rate = Passed / (Passed + Failed) × 100
- N/A items are excluded from the pass rate calculation
1. General Rules
| # | Description | Result | Comments |
|---|---|---|---|
| 1.1 | Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER. | 🟢 | Every populated span traces to ER text: protocol cells to ER lines 369/377/381, benefits to the ER Expected Benefits headings, risks to the Potential Risks & Side Effects headings, gates to lines 310-343, monitoring table to lines 454-463, cadence to line 452, qualitative items to lines 467-472. |
| 1.2 | Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing. | 🟢 | “without a placebo” (at_a_glance) and “with no placebo group” (time_3_sub) mirror ER lines 494 and 176; “Speculative” tiers carried over unchanged. |
| 1.3 | The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”). | 🟢 | Contraindication strength preserved, e.g. ER line 340 “unless the total dose is being managed by the prescribing neurologist” → “outside neurologist supervision”; selective MAO-B inhibitors remain a caution, non-selective MAOIs remain a contraindication. |
| 1.4 | The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc. | 🟢 | Contraindications and Key Interactions both drawn only from the ER Key Interactions & Contraindications section; no Benefit-Modifying Factors or Risk-Modifying Factors content appears in the gates. |
| 1.5 | PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact. | 🟢 | No PMIDs, citations, NCT IDs or expert names anywhere in the QRS; the ER’s brand mentions (DopaBean, Nutricost, NOW Foods) are correctly absent. Generic drug names in the gates all appear in ER lines 310-332 for the same facts. |
| 1.6 | The QRS does not introduce new attributions. | 🟢 | No attributions of any kind in the QRS body. |
2. Focus, Tone & Audience
| # | Description | Result | Comments |
|---|---|---|---|
| 2.1 | The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing. | 🟢 | Flat, declarative, evidence-first register matching the ER throughout. |
| 2.2 | The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging | 🟢 | Quantified targets and dose ranges alongside plain-language framing; no alarmism, no hype. |
| 2.3 | The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor | 🟢 | Facts are stated, not directed; no imperatives in the document’s own voice. |
| 2.4 | The QRS avoids language that implies medical or clinical advice | 🟢 | No “recommend”, “should”, “must”, “advise” anywhere in the body; the only modal, “is best taken before 4 p.m.”, is verbatim ER line 377. |
| 2.5 | The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising” | 🟢 | All cells are descriptive statements of what the ER reports. |
| 2.6 | The QRS never addresses “the reader” directly — it presents evidence, not guidance | 🟢 | No second-person or first-person-plural pronouns present. |
| 2.7 | The QRS is written in plain language, avoiding unnecessary medical jargon | 🟢 | Retained technical terms (dyskinesia, orthostatic, Child-Pugh Class C) are load-bearing decision-gate qualifiers required by items 8.5/9.5; “pyridoxine (vitamin B6)” is glossed as in the ER. |
| 2.8 | Information is presented in a concise and very compact manner | 🟢 | A 499-line ER reduced to roughly 5,500 characters of sheet text with all magnitudes, citations and rationale stripped. |
| 2.9 | It DOES NOT address the reader directly | 🟢 | Confirmed by full-file scan for second-person address; none found. |
| 2.10 | The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review. | 🟢 | Sheet assumes lab access, batch-level product scrutiny and self-tracking. |
| 2.11 | The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort. | 🟢 | Split dosing, eight-marker panel and a staged cadence with batch-triggered resets all assume high compliance. |
| 2.12 | The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort. | 🟢 | Functional biomarker targets tighter than conventional lab ranges; not general-population framing. |
| 2.13 | Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience. | 🟢 | At-a-glance foregrounds label unreliability and the twelve-month evidence ceiling, the two facts that matter most to a self-directed user. |
| 2.14 | The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim. | 🟢 | No occurrence of “anti-aging” or “antiaging” in the file. |
| 2.15 | The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “injection” not “shot”; “adverse event” not “bad reaction”). Direct quotes from sources are exempt. | 🟢 | “myocardial infarction”, “peptic ulcer disease”, “orthostatic”, “glycated haemoglobin” used in the body; the single consumer-register phrase “pharmacy tablet” is verbatim ER line 492 inside the plain-language At-A-Glance. |
3. Template Integrity
| # | Description | Result | Comments |
|---|---|---|---|
| 3.1 | The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why” | 🟢 | All fifteen fixed strings byte-identical to the template. |
| 3.2 | All “<span data-qrs-var=”NAME”>…</span>” from the [qrs_template] are present in the the QRS. | 🟢 | All 34 template variable names present; the repeatable marker_#_* and qualitative_item_# patterns are expanded to 8 marker rows and 6 qualitative items. No template span dropped. |
| 3.3 | Spans that are not addressed in a checklist item are left unchanged | 🟢 | The three non-variable spans (website="evidence_review", website="audit", website="full_review") are unchanged; a structural diff against the template shows no edits outside variable regions. |
4. Formatting
| # | Description | Result | Comments |
|---|---|---|---|
| 4.1 | When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied” | N/A | No ER section feeding the QRS is empty; every tier, gate and monitoring row has source content. |
| 4.2 | Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label. | 🟢 | action_1_label “Whole roasted seed powder (the trial-validated form)”, action_2_label “Split versus single dose”, action_3_label “Best time of day” are verbatim ER bold labels from lines 369, 381, 377. |
| 4.3 | Labels are not paraphrased, abbreviated, or invented. | 🟢 | Marker names verbatim from the ER biomarker table (lines 456-463); time labels taken from the ER’s own wording at lines 424 and 176. |
| 4.4 | The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels. | 🟢 | No emoji in the file; the ER’s “⚠️ Conflicted” marker on the dyskinesia risk is correctly dropped. |
| 4.5 | The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page. | 🟢 | Every section is condensed rather than carried over: benefit and risk tiers reduced to bare ER headings, gate items stripped of rationale and glosses, monitoring rows reduced to marker/target/why with the ER’s Context/Notes column dropped entirely. |
5. Metadata
| # | Description | Result | Comments |
|---|---|---|---|
| 5.1 | The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content. | 🟢 | Lines 2-14, immediately after the doctype and before the template comment at line 16. |
| 5.2 | Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML. | 🟢 | Opening --- at line 3, closing --- at line 13; the preamble text on line 2 sits before the opening delimiter. |
| 5.3 | The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet. | 🟢 | Enclosed in an HTML comment; none of its values appear in the rendered body. |
| 5.4 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | Only duration: "00:03" is quoted, correctly, because it contains a colon. |
| 5.5 | The filename of the source ER is stated as “er_filename: [er_filename]” | 🟢 | Line 4: er_filename: mucuna_pruriens_2026-0825-2346_Opus_ER.md, matching the ER’s own filename field. |
| 5.6 | Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]” | 🟢 | Line 5: qrs_prompt_version: 26.7.02, matching the QRS.md version badge. |
| 5.7 | Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430) | 🟢 | Line 6: qrs_creation_date: 2026-0820-0132, correct format. |
| 5.8 | The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]” | 🟢 | Line 7: qrs_creator_ai_nickname: Opus. |
| 5.9 | The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT) | 🟢 | “Opus” is a single word with no version or qualifier. |
| 5.10 | The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]” | 🟢 | Line 8: qrs_creator_ai_fullname: Opus 5. |
| 5.11 | The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4) | 🟢 | “Opus 5” = nickname plus version, no qualifier. |
| 5.12 | The filename of the document is stated as “qrs_filename: [filename of this document]” | 🟢 | Line 9: qrs_filename: mucuna_pruriens_2026-0825-2346_Opus_QRS.html, matching the file on disk. |
| 5.13 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | All nine keys re-checked; no stray whitespace and no unnecessary quoting. |
6. Page Title & Header
| # | Description | Result | Comments |
|---|---|---|---|
| 6.1 | [page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &) |
🟢 | Line 22: “Mucuna pruriens for Health & Longevity - Quick Reference Sheet”, matching ER canonical_topic with the ampersand encoded. |
| 6.2 | [header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &) |
🟢 | Line 417: “Mucuna pruriens for Health & Longevity”. |
| 6.3 | [header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY] | 🟢 | Line 421: “08/20/2026”, the correct reformat of 2026-0820-0132. |
| 6.4 | [header_subline_model] is set to [qrs_creator_ai_fullname] | 🟢 | Line 425: “Opus 5”, matching the frontmatter value. |
| 6.5 | No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker. | 🟢 | Header holds only the title and the template subline; the ER’s “Also known as” list is not carried over. |
7. At-A-Glance Section
| # | Description | Result | Comments |
|---|---|---|---|
| 7.1 | [at_a_glance] is dense, execution-oriented summary of the ER Conclusion section |
🟢 | Compresses all five Conclusion paragraphs (ER lines 492-498) into evidence strength, evidence provenance, leading harms and the evidence ceiling. |
| 7.2 | [at_a_glance] is no longer than 60 words | 🟢 | 59 words. |
| 7.3 | Every fact in [at_a_glance] is supported by a distinct passage in the ER. | 🟢 | Seven claims map to ER lines 492, 494, 494, 496, 496, 496 and 498 respectively. |
| 7.4 | It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead | 🟢 | No acronyms; “active substance”, “movement disorders”, “roasted seed powder”, “labels are unreliable” are all non-specialist wording. |
| 7.5 | It DOES NOT cite specific trials (names, years, sample sizes, p-values) | 🟢 | No trial names, years or sample sizes. |
| 7.6 | It DOES NOT cite effect sizes, relative risks, or statistical results | 🟢 | No numbers other than “twelve months”, a follow-up horizon rather than an effect size. |
8. Contraindications
| # | Description | Result | Comments |
|---|---|---|---|
| 8.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | All nine items trace to ER lines 310-343. |
| 8.2 | [stop_items] represent the Contraindications from the ER | 🟢 | All eight bullets of the ER’s “Populations who should avoid Mucuna pruriens” list are present, plus the two absolute contraindications from lines 310 and 312 (levodopa products, non-selective MAOIs). |
| 8.3 | Individual [stop_items] are formatted as <li></li> | 🟢 | Nine <li> elements inside the stop_items span, lines 569-588. |
| 8.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | Every ER “because…” / “where…” / “carried over from…” clause stripped (e.g. ER line 339 “Narrow-angle glaucoma, where dopaminergic agents can raise intraocular pressure” → “Narrow-angle glaucoma”); no dash-trailing clauses remain. |
| 8.5 | Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | “Child-Pugh Class C”, “below 30 mL/min/1.73 m²” and “within 90 days” all preserved; only the ER’s explanatory glosses inside those parens were trimmed. |
| 8.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | N/A | The ER’s Key Interactions & Contraindications section uses no ranking notation inside parentheses. |
| 8.7 | The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision. |
🟢 | The ER names eight avoidance populations plus two absolute contraindications, and the section is correspondingly populated. |
| 8.8 | If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. <!– empty: ER names no population that should avoid the intervention –> | N/A | The section is not empty. |
9. Key Interactions
| # | Description | Result | Comments |
|---|---|---|---|
| 9.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | All eleven items trace to ER lines 312-332. |
| 9.2 | [caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications | 🟢 | All ten ER caution bullets plus the selective MAO-B carve-out from line 312 are present; the two absolute contraindications correctly appear only in the Contraindications gate. |
| 9.3 | Individual [caution_items] are formatted as <li></li> | 🟢 | Eleven <li> elements inside the caution_items span, lines 596-616. |
| 9.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | All mechanism and mitigation sentences dropped (e.g. ER line 320’s “Iron chelates levodopa… A two-hour separation resolves it” → the bare item); the ER’s “Other interventions —” dash prefix on line 332 is correctly removed. |
| 9.5 | Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | Every ER example-drug list preserved verbatim (selegiline/rasagiline, haloperidol/risperidone/metoclopramide/prochlorperazine, metformin/glipizide/insulin, and the rest). |
| 9.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | N/A | The ER uses no ranking notation inside parentheses in this section. |
| 9.7 | The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used. |
🟢 | The ER lists twelve interaction bullets and the section is correspondingly populated. |
| 9.8 | If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. <!– empty: ER names no interaction that changes how the intervention is used –> | N/A | The section is not empty. |
10. Protocol
| # | Description | Result | Comments |
|---|---|---|---|
| 10.1 | The section is derived from the ER Protocol section |
🟢 | All three action sets come from the ER Therapeutic Protocol bullets at lines 369, 381 and 377. |
| 10.2 | The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section |
🟢 | Form and dose, dose splitting, and timing — the three bullets that determine what is actually taken, in what fractions, and when; the remaining nine bullets are modifiers rather than implementation steps. |
| 10.3 | If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | The ER Therapeutic Protocol section carries twelve bullets, well above three. |
| 10.4 | All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section. |
🟢 | All nine action spans populated; no placeholder text remains. |
11. Time to Effect
| # | Description | Result | Comments |
|---|---|---|---|
| 11.1 | The three sets of [time] items cover the three most important time-to-effect aspects from the ER | 🟢 | Motor/alertness onset and hormonal/semen timing from ER line 424, plus cortisol and state anxiety at three months from ER line 176. |
| 11.2 | The sets are picked and ordered by the magnitude of the related benefit | 🟢 | Ordered High (motor control), Medium (semen and hormones), Low (cortisol), matching the ER’s benefit tiers. |
| 11.3 | If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | Three distinct time-to-effect aspects are present in the ER. |
| 11.4 | All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER. | 🟢 | All nine time spans populated; time_3_sub correctly carries the ER’s “no placebo group” caveat. |
| 11.5 | If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel |
N/A | The ER provides time-to-effect information at line 424, so the section is correctly retained. |
12. Benefits
| # | Description | Result | Comments |
|---|---|---|---|
| 12.1 | The section is derived from the ER Expected Benefits section |
🟢 | All ten benefit items map one-to-one onto the ER’s H4 benefit headings, lines 158-208. |
| 12.2 | Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative] | 🟢 | All four spans present and populated, lines 539-559. |
| 12.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | Every ER Magnitude: line dropped (688% concentration rise, 25-81% cortisol fall, SMD −18.36); items reduced to the ER heading text alone. |
| 12.4 | Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | No parentheses remain in any benefits span. |
| 12.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective <SPAN> is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | N/A | All four benefit tiers carry items in the ER, so no span needed hiding. |
13. Risks
| # | Description | Result | Comments |
|---|---|---|---|
| 13.1 | The section is derived from the ER Potential Risks & Side Effects section |
🟢 | All ten risk items map one-to-one onto the ER’s H4 risk headings, lines 232-292. |
| 13.2 | Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative] | 🟢 | All four spans present and populated, lines 628-652. |
| 13.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | Every ER Magnitude: line dropped (4 of 14 discontinuations, 56% vs 37.5% adverse events, 0-241 mg per serving, SMD 0.97); items reduced to the ER heading text alone. |
| 13.4 | Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | No parentheses remain in any risks span. |
| 13.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective <SPAN> is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | N/A | All four risk tiers carry items in the ER, so no span needed hiding. |
14. Monitoring
| # | Description | Result | Comments |
|---|---|---|---|
| 14.1 | The section is derived from the ER Monitoring section |
🟢 | Table rows drawn from the ER Monitoring Protocol & Defining Success biomarker table, lines 454-463. |
| 14.2 | All measurable/quantifiable biomarkers from the Monitoring section are listed |
🟢 | All eight ER biomarkers present with matching targets and “Why Measure It?” text: prolactin, total and free testosterone, semen analysis, morning cortisol, fasting glucose and glycated haemoglobin, seated and standing blood pressure, metabolic panel and complete blood count, homocysteine. |
| 14.3 | [monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty. |
🟢 | Lines 786-791 carry the full ER cadence from line 452, including the batch-change reset of the two-week check. |
15. Qualitative Assessment
| # | Description | Result | Comments |
|---|---|---|---|
| 15.1 | The section is derived from the ER Monitoring section |
🟢 | Items taken from the ER’s qualitative-marker list at lines 467-472. |
| 15.2 | All subjective/qualitative biomarkers from the Monitoring section are listed |
🟢 | All six ER qualitative markers present and in ER order: morning drive, afternoon slump, sleep onset and awakenings, nausea and appetite, libido and refractory period, involuntary movement and compulsive behaviour. |
Issues 20/08/2026 01:48
Pass rate 100.00%. No issues found.
Issues 20/08/2026 01:40
- 2.15 — Colloquial verb in at-a-glance: [at_a_glance] (line 436) reads “matched or beat standard preparations”, using the colloquial “beat” where the ER’s own conclusion (line 494) uses the formal “matched or outperformed”.
Fixes 20/08/2026 01:40
- 2.15 — Colloquial verb in at-a-glance: Replaced “matched or beat standard preparations” with “matched or outperformed standard preparations” in [at_a_glance], restoring the ER’s formal wording; the section remains at 59 words.